Vermillion, Inc. (NASDAQ:VRML) shares were trading higher on Wednesday, after the company announced it completed validation of new pre-surgical test offerings with OVA1 plus, including coronavirus antibody testings.
The company is also expected to join the Russell 3000 Index on June 29.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Vermillion is a diagnostic service and bio-analytic solutions provider company. It is engaged in the business of developing and commercializing diagnostic tests for the gynecologic disease. The company's products include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor. It serves clinical reference laboratories, hospital laboratories, and physician offices. Geographically all the operations are functioned from the region of U.S.
Vermillion shares are trading up 7.13% at $4.81 at time of publication on Wednesday. The stock has a 52-week high of $5.78 and a 52-week low of 35 cents.